ChemicalBook
Chinese english Japan Germany
ChemicalBook > 製品カタログ > API > 神経系薬 > その他の神経系薬 > フルラゼパム

フルラゼパム

フルラゼパム price.
  • ￥8920 - ￥20900
  • 化学名: フルラゼパム
  • 英語名: FLURAZEPAM
  • 別名:7-クロロ-1-[2-(ジエチルアミノ)エチル]-5-(2-フルオロフェニル)-1,3-ジヒドロ-2H-1,4-ベンゾジアゼピン-2-オン;1-[2-(ジエチルアミノ)エチル]-5-[2-フルオロフェニル]-7-クロロ-1H-1,4-ベンゾジアゼピン-2(3H)-オン;1-[2-(ジエチルアミノ)エチル]-5-(2-フルオロフェニル)-7-クロロ-1H-1,4-ベンゾジアゼピン-2(3H)-オン;7-クロロ-1-[2-(ジエチルアミノ)エチル]-2,3-ジヒドロ-5-(o-フルオロフェニル)-1H-1,4-ベンゾジアゼピン-2-オン;フルラゼパム;7-クロロ-1-(2-ジエチルアミノエチル)-5-(2-フルオロフェニル)-1H-1,4-ベンゾジアゼピン-2(3H)-オン;フルラゼパム 溶液;フルラゼパム (JAN);7-クロロ-1-[2-(ジエチルアミノ)エチル]-5-(2-フルオロフェニル)-2,3-ジヒドロ-1H-1,4-ベンゾジアゼピン-2-オン
  • CAS番号: 17617-23-1
  • 分子式: C21H23ClFN3O
  • 分子量: 387.88
  • EINECS:241-591-7
  • MDL Number:MFCD00057324
価格2 プロパティ 安全情報 説明
2物価
選択条件：
ブランド
  • 富士フイルム和光純薬株式会社(wako)
  • Sigma-Aldrich Japan
パッケージ
  • 500mg
  • 1ml
  • 生産者富士フイルム和光純薬株式会社(wako)
  • 製品番号W01W0106-0380
  • 製品説明フルラゼパム 99.0+% (Titration)
  • 英語製品説明Flurazepam 99.0+% (Titration)
  • 包装単位500mg
  • 価格￥20900
  • 更新しました2020-09-21
  • 購入
  • 生産者Sigma-Aldrich Japan
  • 製品番号F-003
  • 製品説明フルラゼパム 溶液 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material
  • 英語製品説明Flurazepam solution 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material
  • 包装単位1ml
  • 価格￥8920
  • 更新しました2023-06-01
  • 購入
生産者 製品番号 製品説明 包装単位 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01W0106-0380 フルラゼパム 99.0+% (Titration)
Flurazepam 99.0+% (Titration)		 500mg ￥20900 2020-09-21 購入
Sigma-Aldrich Japan F-003 フルラゼパム 溶液 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material
Flurazepam solution 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material		 1ml ￥8920 2023-06-01 購入

プロパティ

融点  :77-82°
沸点  :551.4±50.0 °C(Predicted)
比重(密度)  :1.2089 (estimate)
闪点  :9℃
貯蔵温度  :2-8°C
溶解性 :45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: <6 mg/mL
酸解離定数(Pka) :pKa 1.90±0.05(H2O) (Uncertain);8.16±0.05 (Uncertain)
外見  :solid
色 :light yellow
EPAの化学物質情報 :2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro- (17617-23-1)

安全情報

絵表示(GHS): Flame (GHS02)Skull and Crossbones (GHS06)Health Hazard (GHS08)
注意喚起語: Danger
危険有害性情報:
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H225 引火性の高い液体および蒸気 引火性液体 2 危険 P210,P233, P240, P241, P242, P243,P280, P303+ P361+P353, P370+P378,P403+P235, P501
H370 臓器の障害 特定標的臓器有害性、単回暴露 1 危険 P260, P264, P270, P307+P311, P321,P405, P501
注意書き:
P210 熱/火花/裸火/高温のもののような着火源から遠ざ けること。－禁煙。
P260 粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。
P280 保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。
P301+P310 飲み込んだ場合：直ちに医師に連絡すること。
P311 医師に連絡すること。
P370+P378 火災の場合：消火に．．．を使用すること。
P403+P235 換気の良い場所で保管すること。涼しいところに 置くこと。

説明

Flurazepam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam

関連製品価格

5-(フェニル)-1H-1,4-ベンゾジアゼピン-2(3H)-オン ベンゾフェノンイミン 7-クロロ-1,3-ジヒドロ-5-(2-フルオロフェニル)-2H-1,4-ベンゾジアゼピン-2-オン 2,5-ジアミノピリジン二塩酸塩 メトトレキサート水和物 塩酸フルラゼパム ジアゼパム ベンズヒドリリデンメチルアミン 2-フルオロジフェニルメタン

関連商品価格